<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Secondary acute myeloid leukaemia with 7q- complicating azathioprine treatment for rheumatoid arthritis [1]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>Mok, CC; Kwong, YL; Lau, CS</td>
</tr>
<tr>
<td><strong>Citation</strong></td>
<td>Annals Of The Rheumatic Diseases, 1995, v. 54 n. 2, p. 155-156</td>
</tr>
<tr>
<td><strong>Issued Date</strong></td>
<td>1995</td>
</tr>
<tr>
<td><strong>URL</strong></td>
<td><a href="http://hdl.handle.net/10722/45015">http://hdl.handle.net/10722/45015</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.; Annals of the Rheumatic Diseases: the EULAR journal. Copyright © B M J Publishing Group.</td>
</tr>
</tbody>
</table>
Severe, disseminated, life threatening herpes zoster infection in a patient with rheumatoid arthritis treated with methotrexate

It was interesting to read the paper by van der Veen and colleagues on the frequency and type of infections in patients with rheumatoid arthritis (RA) treated with methotrexate.1 Their experience concurs with that of Antonelli et al2 who concluded that herpes varicella zoster infection in patients with RA receiving methotrexate therapy appears to be self limiting and benign. I wish to report a case of severe and systemic herpes zoster infection in a patient with RA receiving methotrexate.

In April 1994, a 26 year old white woman presented to her general practitioner with a characteristic (but non-pruritic) chicken pox rash. She was receiving methotrexate 20 mg weekly (Fridays), folic acid 20 mg weekly (Tuesdays) and hydroxychloroquine 200 mg daily for RA. Her RA had started when she was aged 16, and it had either temporarily or partially responded to ketoprofen, mycophenolate mofetil, and sulphasalazine in the past. Methotrexate was commenced at 7.5 mg weekly in February 1993. This was effective in suppressing her RA until August 1993 when she experienced a flare up; this was treated with an intramuscular dose of trimacinolone acetonide 80 mg, steroid injections to her elbows, and an increased dose of methotrexate (15 mg weekly). In September 1993, her RA was still troublesome and her methotrexate dosage was increased further to 20 mg weekly. When she was still no better in November 1993, hydroxychloroquine was added to the regimen at 400 mg daily in the first month followed by a maintenance dose of 200 mg daily. Approximately six weeks later, her arthritis went into remission.

One week after she consulted her doctor, the patient’s rash had become so generalised and severe that she was admitted to Timaru Hospital. Her mucous membranes (eyes, mouth, and vagina) were also ulcerated (figure). She also had systemic features: general malaise, pyrexia, tachypnoea, and her blood pressure was always normal. Her full blood count (including a white cell count of 7.9 x 10^9/l) was normal and differential count and liver function tests were normal a week before she developed herpes varicella zoster infection. Three days after admission, her white cell count was 23.6 x 10^9/l with atypical lymphocytes, characteristic of a viral illness. Her liver function tests were also mildly deranged in a hepatic pattern and her albumin decreased to 26 mg/l. Five days after admission, she was mildly dyspnoeic and her chest radiographs, which were normal on admission, had developed features consistent with pulmonary alveolitis. Her alveolitis was probably secondary to disseminated varicella infection, although we were mindful of methotrexate induced pneumonitis.

Regular medication with Maxitrol eye drops was stopped by an ophthalmologist two days before her admission to hospital: all her antirheumatic medications were stopped on admission. She began receiving intravenous hydrocortisone and broadspectrum antibiotics on day 3 of her inpatient treatment. She was also given a course of oral acyclovir although it was later in the course of her infection than was ideal. Supportive therapy including oxygen, analgesia, chlorothiazide and diflam mouth washes, mycstatin pastilles, and hypnotics were also given.

Stevens-Johnson Syndrome was considered as a differential diagnosis and attempts were made to confirm the diagnosis of disseminated varicella acutely by electron microscopy of the vesicle fluid and skin scrapings, but it was not possible to identify any varicella virus. Fortunately, the patient’s condition gradually improved from day 7 of her admission, and she was able to go home on day 16. At the time of her discharge, the diagnosis of disseminated varicella was confirmed by isolation of the virus on culture of the vesicle fluid and by demonstration of an increase in her varicella serology from a titre of 1/8 to 1/256. Her white cell count, liver function tests and chest radiographs were all normal two weeks after her discharge. When reviewed in the clinic five months later, she was left with some scarring of her skin and ketoprofen alone was sufficient to control her RA symptoms.

Although the patient has made a good recovery, her episode of herpes varicella zoster infection was not benign but life-threatening. There are two reports3,4 of disseminated zoster in patients with RA receiving methotrexate, but neither indicates any systemic or other organ involvement beyond the skin. Both reports suggest the acute illnesses in these patients were brief. One of these patients developed disseminated herpes varicella zoster after beginning steroids while receiving chronic low dose methotrexate.4 The patient reported now was also taking another immunomodulating drug, hydroxychloroquine.

Review of the management of this patient suggests zoster specific immune globulin could have been used had she presented within 96 hours of her contact with a relative who had chicken pox, to reduce the severity of her varicella infection. Had there been a more confident diagnosis of varicella pneumonitis, intravenous rather than oral acyclovir should have been used.

D W T CHING

Department of Medicine, Timaru Hospital, Queen Street, Private Bag, Timaru, New Zealand


LETTER TO THE EDITOR

Secondary acute myeloid leukaemia with 7q- complicating azathioprine treatment for rheumatoid arthritis

Cytotoxic agents are used increasingly in autoimmune disorders, with resulting improvement in the control and long term prognosis of these diseases. However, there is evidence that their prolonged use may be associated with increased risks of solid tumours, lymphoproliferative disorders and leukaemias.2,3 Use of alkylating agents, advanced age, long duration of therapy and high cumulative doses are associated risk factors.2,4
A 72 year old Chinese woman was diagnosed to have rheumatoid arthritis in 1979. She was initially treated with non-steroidal anti-inflammatory agents (diclofenac 25 mg three times a day and naproxen 750 mg/day). Because of disease progression, she was given intramuscular myocrisin (aurathomilate sodium) from November 1979 to May 1981 (approximate cumulative dose 2400 mg). The response was unsatisfactory. Penicillamine 750 mg/day was given from July 1981 until May 1983, when proteinuria prevented its further use. Levamisole 300 mg/week was started in July 1983.

Despite this, the condition of the patient’s joints worsened and she underwent bilateral knee replacement in 1985. Levamisole was stopped and azathioprine 100 mg/day was started in January 1986. She continued to improve but developed anaemia (8-8 g/dl) and leucopenia (2-5 x 10^9/l) in March 1993, necessitating reduction of azathioprine to 50 mg/day. Further tests showed iron deficiency, but the patient refused endoscopic examinations. She began taking iron supplements; however, because of persistent anaemia, azathioprine was substituted by sulphasalazine 1-5 g/day in May 1993. The total dose of azathioprine was estimated to be 250 g.

Despite transient improvement in anaemia, her haemoglobin concentration decreased again to 7 g/dl in June 1994. Her white cell count was 1-5 x 10^9/l (80% blasts) and platelet count was 251 x 10^9/l. Bone marrow examination showed 85% blasts. Occasional residual erythroid precursors showed b-nucleation. The morphological diagnosis was acute myeloid leukaemia (AML), M2 according to the French-American-British Classification system for AML.1 Cyto genetic analysis was performed on marrow cells after short term culture, metaphase chromosomes banded by trypsin/Giemsa and karyotyped according to the International System for Human Cytogenetic Nomenclature 1991 Guidelines.2 This showed 46,XX,del(7) (q22q35) (figure) in addition to a normal clone of 46,XX. Detailed enquiry about life-time work history and hobbies3 failed to disclose relevant noxious agents. Although the literature contains a few reports relating long term use of cytotoxics or disease modifying agents in autoimmune disorders with the occurrence of malignancies,4-8 it is difficult to determine if these observations represent a causal relationship or chance occurrence. However, in the present case, several features support the diagnosis of secondary leukaemia. The presence of myelodysplastic features, albeit subtle, in residual haematopoietic elements, together with the one year history of anaemia preceding the leukaemia, suggest a pre-leukaemic phase before the onset of frank leukaemia. The strongest supporting evidence was the chromosomal abnormality. Karyotypic aberrations involving chromosome 7—either deletion of the long arm (7q-) or monosomy (-7)—are common chromosomal aberrations in AML and myelodysplasia,9-10 and are significantly related to leukaemias secondary to toxic exposures including environmental and occupational toxins,11 and previous chemotherapy.12 Thus, 7q(-7) can be considered a characteristic finding in secondary leukaemia.13-14

A detailed examination of the drug history of this patient revealed three candidate causative drugs: myocrisin, penicillamine and azathioprine. Although myocrisin and penicillamine cause myelosuppression and aplastic anaemia, no case of secondary leukaemia or malignancies has been attributed to their use. However, acute leukaemia had been reported in a patient with systemic lupus erythematosus/rheumatoid arthritis overlip syndrome treated with a total cumulative dose of 52 g of azathioprine.13 The authors of that report suggested that, because of the small cumulative dose, further studies were required. With the much greater cumulative dose in our patient (260 g) and the characteristic chromosomal aberration, we conclude that azathioprine was the most likely leukaemogenic drug in our patient.

The incidence of secondary malignancies after the use of cytotoxic agents for non-malignant conditions is admittedly low. As it occurs after prolonged administration of the drugs, physicians should be aware of this complication. Careful clinical monitoring is important and use of these agents should be minimised once the disease is under control.

The authors thank T T Lau for technical assistance in the cytogenetic analysis.